期刊文献+

非小细胞肺癌患者胸腔积液中EGFR基因突变的检测及临床意义 被引量:2

Detection of EGFR mutations and its clinical significance in hydrothorax of patients with non-small cell lung cancer
下载PDF
导出
摘要 目的:探讨采用非小细胞肺癌患者胸腔积液标本肿瘤细胞进行表皮生长因子(epidermal growth factor receptor,EGF R)基因突变检测的可行性及其临床意义。方法:采用Sanger测序法检测17例非小细胞肺癌患者胸腔积液及对应的17例手术或肺部穿刺组织标本EGFR基因18~21外显子基因突变,并进行统计分析。结果:胸腔积液标本17例共检出5例突变,检出率29.41%。手术或穿刺组织标本17例共检出7例突变,检出率41.18%。胸腔积液标本EGFR基因突变检出率略低于手术或穿刺组织标本。结论:采用Sanger测序法进行非小细胞肺癌患者胸腔积液中EGFR基因突变的检测,方法可行,尤其适用于无法获取手术或肺部穿刺组织标本的患者。 Objective: To explore the clinical significance of detecting epidermal growth factor receptor (EGFR) mutations in hydrothorax of patients with non-smaU cell lung cancer (NSCLC). Methods: The mutations of EGFR in exon 18- 21 were detected with Sanger sequencing in 17 hydrothorax samples and 17 tumor tissue samples in parallel from patients with NSCLC. Results: There were 5 cases (29.41%) with EGFR mutations in 17 hydrothorax samples and 7 cases (41.18%) in 17 tumor tissue samples. The detection rate of EGFR mutations in hydrothorax samples was lower than that in tumor tissue samples. Conclusion: The hydrothorax sample can be used to detecting EGFR mutations by Sanger sequencing. And it is helpful to patients with NSCLC who can't obtain tumor tissue.
出处 《临床与病理杂志》 2017年第8期1583-1586,共4页 Journal of Clinical and Pathological Research
基金 无锡市卫计委面上项目(MS201536)~~
关键词 非小细胞肺癌 胸腔积液 EGFR基因 non-small ceil lung cancer hydrothorax epidermal growth factor receptor
  • 相关文献

参考文献1

二级参考文献58

  • 1PM Harari. Epidermal growth factor receptor inhibition strategies in oncology [ J ]. Endocrine- Related Cancer, 2004, 11: 689- 708.
  • 2Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis [ J ]. Eur J Cancer, 2001, 37 (suppl4): S9-S15.
  • 3Paez JG, Janne PA, Lee JC, et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy [ J ]. Science, 2004, 304 (5676): 1497-1500.
  • 4Lynch TJ, Bell DW, Sordella R, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non - Small - Cell Lung Cancer to Gefitinib [J]. N Engl J Med, 350, 21:2129 - 2139.
  • 5Helfrich BA, Raben D, Varella - Garcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, lressa) in non - small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels [ J]. Clin Cancer Res, 2006, 12 (23): 7117-7125.
  • 6Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloal- veolar carcinoma subtype, predict response to erlotinib [ J ]. J Clin Oncol, 2008, 26 (9) : 1472 - 1478.
  • 7Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer [J]. Nat Rev Cancer, 2007, 7: 169-181.
  • 8Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and areassociated with sensitivity of tumors to gefitinib and erlotinib [ J ]. Proc Nail Acad Sci, 2004, 101: 13306-13311.
  • 9Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non - small -cell lungcancer [J]. J Clin Oncol, 2007, 25 (5) : 587 -595.
  • 10Sasaki H, Shimizu S, Endo K, et al. EGFR and erbB2 mutation status in Japanese lung cancer patients [ J ]. Int J Cancer, 2006, 118 (1): 180-184.

共引文献12

同被引文献16

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部